JP Morgan resumed coverage on Emergent BioSolutions
$EBS
Biotechnology: Pharmaceutical Preparations
Health Care
JP Morgan resumed coverage of Emergent BioSolutions with a rating of Underweight
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/30/2024 | $15.00 | Buy | H.C. Wainwright |
| 8/22/2024 | $16.00 | Buy | Rodman & Renshaw |
| 3/7/2024 | $5.00 | Hold → Buy | The Benchmark Company |
| 11/20/2023 | Underweight | JP Morgan | |
| 8/29/2023 | Buy → Hold | The Benchmark Company | |
| 4/10/2023 | $22.00 | Hold → Buy | The Benchmark Company |
| 3/17/2023 | $23.00 → $9.00 | Neutral → Underweight | JP Morgan |
| 11/10/2022 | Buy → Hold | The Benchmark Company |
H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00
Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00
The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00
8-K - Emergent BioSolutions Inc. (0001367644) (Filer)
SCHEDULE 13G - Emergent BioSolutions Inc. (0001367644) (Subject)
SCHEDULE 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of
GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that its Board of Directors authorized the repurchase of up to $50 million of the company's common stock on or before March 31, 2027. This authorization replaces the prior repurchase authorization which permitted Emergent to repurchase up to $50 million of company's common stock by March 27, 2026. Under the prior authorization, Emergent repurchased $24.8 million shares. "In 2025, we were able to return value to shareholders through share repurchases as we continued to make progress on our multi-year transformation," said Joe Papa, president and CEO of Emergent. "This new approval ref
WINNIPEG, Manitoba, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) today announced a series of new contracts and a contract modification with the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to deliver critical medical countermeasures to support Canada's biological threat preparedness and response infrastructure. The multiyear agreements, valued at up to approximately $140 million CAD, build upon over a decade of collaboration between Emergent and Canada and reinforce Canada's commitment to long-term readiness and advanced strategic stockpiling. Emergent will receive more than $35M million CAD in orders in 2026. Under these agreeme
4 - Emergent BioSolutions Inc. (0001367644) (Issuer)
Fourth Quarter 2025 Total Revenues of $148.7 million; Full Year 2025 Total Revenues of $742.9 millionFourth Quarter 2025 Net Loss of $54.6 million and Net Loss Margin of 37%Full Year 2025 Net Income of $52.6 million versus a Net Loss of $190.6 million in the prior yearFull Year 2025 Net Income per diluted share of $0.93 versus a Net Loss per diluted share of $3.60 in the prior yearFull Year 2025 Adjusted Net Income of $86.8 million versus an Adjusted Net Loss of $12.1 million in the prior yearFull Year 2025 Adjusted Net Income per diluted share of $1.53 versus an Adjusted Net Loss per diluted share of $0.23 in the prior yearFull Year 2025 Gross Margin % of 45% and Adjusted Gross Margin % of
GAITHERSBURG, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, February 26, 2026, at 5:00 pm eastern time to discuss the financial results for the fourth quarter and full year of 2025. Participants can access the conference call live via webcast and also by visiting the Investors page of Emergent's website. To participate via telephone, please register in advance at this link. Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of
Third Quarter 2025 Total Revenues of $231.1 million, above the high end of Q3 guidance by $21.0 millionThird Quarter 2025 Net Income of $51.2 million and Net Income Margin of 22%Third Quarter 2025 Gross Margin % of 54% and Adjusted Gross Margin % of 61%, an expansion of 300 bps and 200 bps, respectively, versus prior yearThird Quarter 2025 Adjusted EBITDA of $87.8 million and Adjusted EBITDA Margin of 38%Raising the Full Year 2025 Revenue and Profitability GuidanceStrong Sequential Naloxone Revenue Growth, Primarily Driven by NARCAN® Nasal Spray, QoQ Through Q3 2025 GAITHERSBURG, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today reported financial results
SC 13G - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
SC 13G/A - Emergent BioSolutions Inc. (0001367644) (Subject)
GAITHERSBURG, Md., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE:EBS) announced today that Dr. Louis W. Sullivan will retire from the company's Board of Directors effective November 14 after 19 years of service to the company and its shareholders. "For nearly two decades, Dr. Sullivan has been a trusted advisor and champion of Emergent's mission to protect and save lives," said Joe Papa, president and CEO of Emergent. "On behalf of the Board and the entire Emergent team, I want to thank him for his distinguished leadership and contributions. We wish him all the best." Dr. Sullivan served on Emergent's Board of Directors since 2006, and most recently served as chair of the
Executive Management Team appointments contribute to Emergent's transformation and beyond, including promotion of Jessica Perl to General Counsel and Corporate Secretary GAITHERSBURG, Md., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS), a global company providing solutions that address public health threats and delivering life-extending products to market, today announced the appointment of Simon Lowry, M.D., as chief medical officer, head of research and development, effective November 18. Dr. Lowry will be responsible for advancing Emergent's strategic scientific roadmap, and will oversee research and development, regulatory affairs, medical affairs, clinical an
Ongoing support of the ‘White House Challenge to Save Lives from Overdose' through workplace and public safety measuresOne-year mark of Ready to Rescue public awareness campaign to expand awareness, particularly among young adults and vulnerable communities20,000 additional doses of NARCAN® Nasal Spray to be donated to organizations in need GAITHERSBURG, Md., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) remains committed to supporting widespread opioid emergency preparedness by expanding access to NARCAN® Nasal Spray and educating the public on how to respond to an opioid overdose. As opioid overdose fatalities have risen in the workplace in recent years,1 Emerg